TY - JOUR
T1 - Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
AU - Hum, Ryan M.
AU - Kanigicherla, Durga A.
AU - Ho, Pauline
PY - 2022/10/17
Y1 - 2022/10/17
N2 - We present a case of Certolizumab-associated renal sarcoidosis, the first reported case in a patient with psoriatic arthritis (PsA) that was effectively treated with corticosteroids. A 55-year-old Caucasian man with PsA diagnosed age 47, and plaque psoriasis since his early twenties, was on Certolizumab Pegol for 7 months before presenting to the emergency department with seizures and renal failure. A renal biopsy confirmed renal sarcoidosis. His Certolizumab Pegol therapy was stopped, and after several months taking prednisolone at a reducing regime, his renal function improved, and his PsA remained under control. When considering further treatment options for his PsA keeping in mind that other drugs, especially tumour-necrosis-factor-alpha inhibitors (TNFi), have been reported to be associated with sarcoidosis, Tofacitinib was considered to be a future treatment option acceptable to the patient given current NICE guidelines approving its use in PsA, and the lack of reports of Tofacitinib-associated sarcoidosis in the literature.
AB - We present a case of Certolizumab-associated renal sarcoidosis, the first reported case in a patient with psoriatic arthritis (PsA) that was effectively treated with corticosteroids. A 55-year-old Caucasian man with PsA diagnosed age 47, and plaque psoriasis since his early twenties, was on Certolizumab Pegol for 7 months before presenting to the emergency department with seizures and renal failure. A renal biopsy confirmed renal sarcoidosis. His Certolizumab Pegol therapy was stopped, and after several months taking prednisolone at a reducing regime, his renal function improved, and his PsA remained under control. When considering further treatment options for his PsA keeping in mind that other drugs, especially tumour-necrosis-factor-alpha inhibitors (TNFi), have been reported to be associated with sarcoidosis, Tofacitinib was considered to be a future treatment option acceptable to the patient given current NICE guidelines approving its use in PsA, and the lack of reports of Tofacitinib-associated sarcoidosis in the literature.
M3 - Article
SN - 2053-8855
JO - Oxford Medical Case Reports
JF - Oxford Medical Case Reports
ER -